When a chest tube is placed, it can be hard for the fluid to drain. Tissue plasminogen activator and DNase are given through the chest tube to help with draining the fluid. We are doing this research to see if early addition of tPA-DNase will help with better fluid draining.
Patients scheduled for thoracic surgery will be identified as potential candidates and recruited by a research coordinator before surgery. Research subjects will be randomized to either early or late post-operative urinary catheter (a thin flexible tube placed into the bladder to drain urine) removal. Thoracic epidural analgesia (TEA), a thin tube placed near the spinal cord, will remain functioning after urinary catheter removal for the early group. The study group randomized to early catheter removal will have urinary catheters removed 24 hours after surgery is completed. Study subjects that are randomized to late removal of urinary catheter will have urinary catheters removed after TEA is discontinued as routine clinical care (usually 4-5 days). Determination of bladder urine volume will be made by sound wave examination (ultrasound) by appropriately-trained staff. Following indwelling urinary catheter removal, research subjects may receive a brief urine drain tube as standard clinical care. Laboratory urine analysis will be obtained from urine following removal of urinary catheter and assessed for urinary tract infection (UTI).
This study is for patients who have received a kidney, liver, or pancreas transplant and who have developed resistant Cytomegalovirus infection. There will be two treatment groups to compare the improvement or resolution of Cytomegalovirus infection. Subjects will be randomized to receive 8 weeks of either the investigational drug, Maribavir, or physician assigned standard of care treatment.
The intention of this study is to collect the laboratory data, safety, and tolerability information on Posaconazole (POS) administered through IV and oral solution to neutropenic pediatric subjects, or pediatric subjects who are expected to become neutropenic , and who are at risk of developing Invasive Fungal Infections (IFI). The subjects will range in age from 2 years to 17 years of age. This age range represents the pediatric population at risk of developing IFI for which data are lacking. The study design includes an assessment of safety for all treated subjects at each dose level for each age group employing rapid data collection and centralized analysis.
Non-cystic fibrosis (CF) bronchiectasis is a lung disease characterized by dilation of the airways. Patients often suffer from chronic airways infection. One such associated infection is non-tuberculosis mycobacterium (NTM) lung disease, which is 50 to 75 times more common in patients with bronchiectasis than those without it. The decision to initiate treatment (for NTM pulmonary disease) is not straightforward, hinging on how the patient feels and excluding other causes for their symptoms. Symptoms patients frequently report are pulmonary related (e.g. cough, sputum production, and coughing up blood) and constitutional symptoms (e.g. fevers, weight loss and body aches). When treatment is started for NTM lung disease, it can be for many months to years and has many potential side effects. The scientific literature rarely reports outcomes of treatment from a patient?s perspective, which could aid a physician?s decision to initiate treatment and/or response to treatment of the patient?s NTM disease. This study will 1) create a Patient Registry for patients with bronchiectasis and/or NTM disease with an emphasis on patient reported outcomes (PRO) using questionnaires and 2) prospectively collect and analyze the clinical data for patients seen in the MUSC Bronchiectasis and/or NTM clinic
This pilot study is designed as a preliminary study to determine if a significant difference exists in the stool bacterial diversity of hospitalized patients on broad-spectrum antibiotics during different points in their course of therapy. Fecal samples will be collected from study subjects at pre-defined time intervals (baseline, >48 to 96 to 144 to <192 hours) during their course of antibiotic therapy. Stool samples will be analyzed for the number and abundance (diversity) of bacterial species present.
This is a study comparing two methods of dressing a post operative wound that are currently in practice. One method is a traditional dry gauze dressing. The other method is using a negative pressure dressing that provides gentle suction on the wound.
We will attempt to determine how well the use of post-operative negative pressure dressing reduces wound healing problems in patients who have surgery after radiation for a sarcoma in the thigh or leg.
Treatment of chronic hepatitis C virus (HCV) infection is now possible with all oral medications. While most patients achieve a sustained virologic response (SVR) after treatment, synonymous with cure, some patients relapse after treatment for reasons that are unclear. The goal of this research is to understand how a person's immune system changes during treatment of HCV infection with all oral therapy, and how these changes might impact the chances of relapse after treatment. To address these questions, blood and clinical information will be collected from study participants over the course of receiving standard of care treatment for HCV infection. This blood and clinical information will be used to conduct laboratory research focused on the immune system.